ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2011
Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center.Indian journal of surgical oncology · 2025Article
- Patterns of Subsequent Cancer Incidence Over Time in Patients with Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Risk factors of developing contralateral breast cancer after first primary breast cancer treatment.Cancer reports (Hoboken, N.J.) · 2024Article
- Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.Cancer research · 2022Article
- Characterization of transcriptome diversity and in vitro behavior of primary human high-risk breast cells.Scientific reports · 2022Article
- The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women.Breast cancer (Tokyo, Japan) · 2022Article
- Relationship between metastasis and second primary cancers in women with breast cancer.Frontiers in oncology · 2022Article
- Race, ethnicity and risk of second primary contralateral breast cancer in the United States.International journal of cancer · 2021Article
- Prevalence of Germline Pathogenic and Likely Pathogenic Variants in Patients With Second Breast Cancers.JNCI cancer spectrum · 2020Article
- Problems to affect long-term survival for breast cancer patients: An observational study of subsequent lung/bronchus malignancies.Medicine · 2018Observational
- Molecular Subtypes and Local-Regional Control of Breast Cancer.Surgical oncology clinics of North America · 2018Review
- Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.Breast cancer research : BCR · 2017Article
- Disparities in contralateral prophylactic mastectomy use among women with early-stage breast cancer.NPJ breast cancer · 2017Article
- Does estrogen receptor determination affect prognosis in early stage breast cancers?International journal of clinical and experimental medicine · 2015Article
- Bilateral breast cancers.Nature reviews. Clinical oncology · 2014Review
- Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.Breast cancer research and treatment · 2012Article
- Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis.Journal of carcinogenesis · 2011Article
- A Rare Case of Triple Positive Metachronous Breast Cancer.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectivesHormone-receptor (HR) and HER2/neu-receptor (HER2) status of breast tumors are important indicators for targeted therapies. We examine the association of receptor status and risk for a second breast cancer.
methodsWe analyzed data on 106,331 women in the California Cancer Registry whose first cancer is locoregional invasive breast disease, diagnosed from 1999 through 2005, yielding 1,613 second primary breast cancers. Standardized incidence ratios (SIR) with 95% confidence intervals (CIs) were used to evaluate risk of second tumors, accounting for age at first diagnosis, duration at risk, and race/ethnicity.
resultsAmong non-Hispanic whites, HR-positive first tumors signal a reduction in risk for second breast cancers (SIR = 0.83, 95% CI: 0.77-0.89) whereas HR-negative status signals elevated risk (SIR = 1.48, 95% CI: 1.29-1.70). Asian/Pacific Islanders, African Americans, and Hispanics are at elevated risk of second breast cancers regardless of HR status of the first tumor. Hispanics with HR-negative first tumors are at greater risk than those with HR-positive disease (HR(-): SIR = 3.76, 95% CI: 2.97-4.71; HR(+): SIR = 1.86, 95% CI: 1.56-2.20). HER2 status does not differentiate risk for second tumors in any group examined.
conclusionsHR status of a first breast cancer is a marker for risk of a second breast cancer. HER2 status does not seem to be a marker of risk for a second breast cancer. Risk differences across race/ethnic groups by HR status suggest heterogeneity of breast cancers across race/ethnicity. IMPACT: These data suggest that HR status may be helpful in shaping strategies to reduce risk of a second breast cancer, while HER2 status seems uninformative for this purpose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.